You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlanzapine
Accession NumberDB00334  (APRD00138)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionOlanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.
Structure
Thumb
Synonyms
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Olanzapin
Olanzapina
Olanzapine
Olanzapinum
Zyprexa
External Identifiers
  • LY 170053
  • UNII-X7S6Q4MHCB
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-olanzapine ODTTablet, orally disintegrating5 mgOralBgp Pharma Ulc2014-09-172015-12-31Canada
Abbott-olanzapine ODTTablet, orally disintegrating10 mgOralAbbott Laboratories, Limited2014-09-172015-12-31Canada
Abbott-olanzapine ODTTablet, orally disintegrating15 mgOralAbbott Laboratories2014-12-032015-12-31Canada
Accel-olanzapineTablet5 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet15 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet20 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-olanzapineTablet7.5 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet2.5 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapineTablet10 mgOralAccel Pharma Inc2014-09-042015-11-09Canada
Act OlanzapineTablet15 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Act OlanzapineTablet5 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Act OlanzapineTablet20 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Act OlanzapineTablet7.5 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Act OlanzapineTablet10 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Act OlanzapineTablet2.5 mgOralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapine ODTTablet, orally disintegrating15 mgOralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTTablet, orally disintegrating20 mgOralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTTablet, orally disintegrating5 mgOralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTTablet, orally disintegrating10 mgOralActavis Pharma Company2009-10-16Not applicableCanada
Auro-olanzapine ODTTablet, orally disintegrating15 mgOralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTTablet, orally disintegrating20 mgOralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTTablet, orally disintegrating5 mgOralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTTablet, orally disintegrating10 mgOralAuro Pharma Inc2015-12-01Not applicableCanada
Ava-olanzapineTablet7.5 mgOralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapineTablet10.0 mgOralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapineTablet2.5 mgOralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapineTablet15.0 mgOralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapineTablet5.0 mgOralAvanstra Inc2011-11-232014-08-21Canada
Dom-olanzapineTablet2.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapineTablet15 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapineTablet5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapineTablet7.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapineTablet10 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTTablet, orally disintegrating5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTTablet, orally disintegrating10 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTTablet, orally disintegrating15 mgOralDominion PharmacalNot applicableNot applicableCanada
Ipg-olanzapineTablet15 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapineTablet2.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapineTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapineTablet5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapineTablet7.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapineTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTTablet, orally disintegrating5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTTablet, orally disintegrating10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTTablet, orally disintegrating15 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTTablet, orally disintegrating20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp Olanzapine FcTablet10 mgOralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine FcTablet2.5 mgOralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine FcTablet15 mgOralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine FcTablet5 mgOralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine FcTablet20 mgOralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine FcTablet7.5 mgOralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine ODTTablet, orally disintegrating15 mgOralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTTablet, orally disintegrating20 mgOralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTTablet, orally disintegrating5 mgOralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTTablet, orally disintegrating10 mgOralJamp Pharma Corporation2014-08-01Not applicableCanada
Mar-olanzapineTablet5 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapineTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-olanzapineTablet7.5 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapineTablet10 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapineTablet2.5 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapineTablet15 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapine ODTTablet, orally disintegrating10 mgOralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTTablet, orally disintegrating15 mgOralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTTablet, orally disintegrating20 mgOralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTTablet, orally disintegrating5 mgOralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mint-olanzapineTablet10 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapineTablet2.5 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapineTablet15 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapineTablet5 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapineTablet20 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapineTablet7.5 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapine ODTTablet, orally disintegrating15 mgOralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTTablet, orally disintegrating20 mgOralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTTablet, orally disintegrating5 mgOralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTTablet, orally disintegrating10 mgOralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mylan-olanzapineTablet2.5 mgOralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapineTablet15 mgOralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapineTablet5 mgOralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapineTablet20 mgOralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapineTablet7.5 mgOralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapineTablet10 mgOralMylan Pharmaceuticals Ulc2010-05-16Not applicableCanada
Mylan-olanzapine ODTTablet, orally disintegrating20 mgOralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTTablet, orally disintegrating5 mgOralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTTablet, orally disintegrating10 mgOralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTTablet, orally disintegrating15 mgOralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Ntp-olanzapineTablet5.0 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapineTablet7.5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapineTablet10.0 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapineTablet2.5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapineTablet15.0 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-olanzapineTablet2.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapineTablet15.0 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapineTablet5.0 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapineTablet7.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapineTablet10.0 mgOralNu Pharm IncNot applicableNot applicableCanada
OlanzapineTablet5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
OlanzapineTablet20 mgOralPro Doc Limitee2014-06-10Not applicableCanada
OlanzapineTablet7.5 mgOralPro Doc Limitee2010-02-01Not applicableCanada
OlanzapineTablet20 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
OlanzapineTablet15 mgOralSanis Health Inc2011-10-26Not applicableCanada
OlanzapineTablet20 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
OlanzapineTablet5 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
OlanzapineTablet2.5 mgOralSanis Health Inc2011-10-26Not applicableCanada
OlanzapineTablet7.5 mgOralMeliapharm Inc2011-10-182014-06-25Canada
OlanzapineTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
OlanzapineTablet10 mgOralNovopharm LimitedNot applicableNot applicableCanada
OlanzapineTablet7.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
OlanzapineTablet10 mgOralPro Doc Limitee2010-02-01Not applicableCanada
OlanzapineTablet2.5 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
OlanzapineTablet2.5 mgOralNovopharm LimitedNot applicableNot applicableCanada
OlanzapineTablet7.5 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
OlanzapineTablet5 mgOralSanis Health Inc2011-10-26Not applicableCanada
OlanzapineTablet10 mgOralMeliapharm Inc2011-10-182014-06-25Canada
OlanzapineTablet15 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
OlanzapineTablet15 mgOralNovopharm LimitedNot applicableNot applicableCanada
OlanzapineTablet10 mg/1OralREMEDYREPACK INC.2013-07-222016-10-13Us
OlanzapineTablet10 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
OlanzapineTablet2.5 mgOralMeliapharm Inc2011-10-182014-06-25Canada
OlanzapineTablet5 mgOralNovopharm LimitedNot applicableNot applicableCanada
OlanzapineTablet15 mgOralPro Doc Limitee2010-02-01Not applicableCanada
OlanzapineTablet5 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
OlanzapineTablet2.5 mgOralPro Doc Limitee2010-02-01Not applicableCanada
OlanzapineTablet10 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
OlanzapineTablet7.5 mgOralSanis Health Inc2011-10-26Not applicableCanada
OlanzapineTablet15 mgOralMeliapharm Inc2011-10-182014-06-25Canada
OlanzapineTablet2.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
OlanzapineTablet5 mgOralMeliapharm Inc2011-10-182014-06-25Canada
OlanzapineTablet5 mg/1OralREMEDYREPACK INC.2013-04-292016-10-13Us
OlanzapineTablet15 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
OlanzapineTablet2.5 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
OlanzapineTablet7.5 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
OlanzapineTablet7.5 mgOralNovopharm LimitedNot applicableNot applicableCanada
OlanzapineTablet5 mgOralPro Doc Limitee2010-02-01Not applicableCanada
OlanzapineTablet20 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
OlanzapineTablet15 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
OlanzapineTablet10 mgOralSanis Health Inc2011-10-26Not applicableCanada
Olanzapine for InjectionPowder, for solution10 mgIntramuscularSandoz Canada Incorporated2014-07-22Not applicableCanada
Olanzapine ODTTablet, orally disintegrating20 mgOralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTTablet, orally disintegrating10 mgOralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTTablet, orally disintegrating15 mgOralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTTablet, orally disintegrating5 mgOralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTTablet, orally disintegrating5 mgOralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTTablet, orally disintegrating15 mgOralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTTablet, orally disintegrating20 mgOralSanis Health IncNot applicableNot applicableCanada
Olanzapine ODTTablet, orally disintegrating10 mgOralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTTablet, orally disintegrating20 mgOralPro Doc Limitee2014-06-10Not applicableCanada
Olanzapine ODTTablet, orally disintegrating10 mgOralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTTablet, orally disintegrating5 mgOralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTTablet, orally disintegrating15 mgOralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTTablet, orally disintegrating15 mgOralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTTablet, orally disintegrating10 mgOralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTTablet, orally disintegrating5 mgOralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine-odtTablet, orally disintegrating20 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odtTablet, orally disintegrating5 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odtTablet, orally disintegrating10 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odtTablet, orally disintegrating15 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
PHL-olanzapineTablet10 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapineTablet2.5 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapineTablet15 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapineTablet5 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapineTablet7.5 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapine ODTTablet, orally disintegrating10 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapine ODTTablet, orally disintegrating15 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-olanzapine ODTTablet, orally disintegrating5 mgOralPharmel Inc2010-02-182016-10-25Canada
PMS-olanzapineTablet2.5 mgOralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapineTablet15 mgOralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapineTablet5 mgOralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapineTablet7.5 mgOralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapineTablet20 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-olanzapineTablet10 mgOralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapine ODTTablet, orally disintegrating15 mgOralPharmascience Inc2009-10-15Not applicableCanada
PMS-olanzapine ODTTablet, orally disintegrating20 mgOralPharmascience Inc2014-07-29Not applicableCanada
PMS-olanzapine ODTTablet, orally disintegrating5 mgOralPharmascience Inc2009-10-15Not applicableCanada
PMS-olanzapine ODTTablet, orally disintegrating10 mgOralPharmascience Inc2009-10-15Not applicableCanada
Ran-olanzapineTablet5.0 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapineTablet7.5 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapineTablet10.0 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapineTablet2.5 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapineTablet15.0 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapine IrTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine IrTablet7.5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine IrTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine IrTablet2.5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine IrTablet15 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine IrTablet5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine ODTTablet, orally disintegrating5 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTTablet, orally disintegrating10 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTTablet, orally disintegrating15 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTTablet, orally disintegrating20 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Riva-olanzapineTablet7.5 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapineTablet10 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapineTablet2.5 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapineTablet15 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapineTablet5 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTTablet, orally disintegrating5 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTTablet, orally disintegrating20 mgOralLaboratoire Riva Inc2014-06-12Not applicableCanada
Riva-olanzapine ODTTablet, orally disintegrating10 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTTablet, orally disintegrating15 mgOralLaboratoire Riva Inc2010-02-17Not applicableCanada
Sandoz OlanzapineTablet10.0 mgOralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz OlanzapineTablet2.5 mgOralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz OlanzapineTablet15.0 mgOralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz OlanzapineTablet20.0 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz OlanzapineTablet5.0 mgOralSandoz Canada Incorporated2009-12-06Not applicableCanada
Sandoz OlanzapineTablet7.5 mgOralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapine ODTTablet, orally disintegrating15 mgOralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTTablet, orally disintegrating20 mgOralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTTablet, orally disintegrating5 mgOralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTTablet, orally disintegrating10 mgOralSandoz Canada Incorporated2010-02-26Not applicableCanada
Teva-olanzapineTablet20 mgOralTeva Canada Limited2011-04-28Not applicableCanada
Teva-olanzapineTablet5 mgOralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapineTablet7.5 mgOralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapineTablet10 mgOralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapineTablet2.5 mgOralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapineTablet15 mgOralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapine ODTablet, orally disintegrating15 mgOralTeva Canada Limited2010-03-082016-01-18Canada
Teva-olanzapine ODTablet, orally disintegrating20 mgOralTeva Canada Limited2010-03-082016-01-18Canada
Teva-olanzapine ODTTablet, orally disintegrating5 mgOralTeva Canada Limited2010-03-08Not applicableCanada
Teva-olanzapine ODTTablet, orally disintegrating10 mgOralTeva Canada Limited2010-03-08Not applicableCanada
Torrent-olanzapine ODTTablet, orally disintegrating5 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTTablet, orally disintegrating10 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTTablet, orally disintegrating15 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTTablet, orally disintegrating20 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-olanzapineTablet2.5 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapineTablet15 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapineTablet5.0 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapineTablet7.5 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapineTablet10 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapine ODTTablet, orally disintegrating20 mgOralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTTablet, orally disintegrating5 mgOralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTTablet, orally disintegrating10 mgOralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTTablet, orally disintegrating15 mgOralVanc Pharmaceuticals IncNot applicableNot applicableCanada
ZypadheraInjection, powder, for suspension, extended release300 mgIntramuscularEli Lilly Nederland B.V.2008-11-19Not applicableEu
ZypadheraInjection, powder, for suspension, extended release405 mgIntramuscularEli Lilly Nederland B.V.2008-11-19Not applicableEu
ZypadheraInjection, powder, for suspension, extended release210 mgIntramuscularEli Lilly Nederland B.V.2008-11-19Not applicableEu
ZyprexaTablet, coated7.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet2.5 mg/1OralCardinal Health1997-06-23Not applicableUs
ZyprexaTablet20 mg/1OralREMEDYREPACK INC.2013-07-082016-04-05Us
ZyprexaTablet, coated20 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated15 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet5 mg/1OralPhysicians Total Care, Inc.2003-09-30Not applicableUs
ZyprexaTablet5 mg/1OralSTAT Rx USA LLC1996-10-01Not applicableUs
ZyprexaTablet, coated7.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
ZyprexaTablet, coated10 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet5 mg/1OralDispensing Solutions, Inc.1996-10-01Not applicableUs
ZyprexaTablet10 mg/1OralCardinal Health1996-10-01Not applicableUs
ZyprexaTablet10 mg/1OralREMEDYREPACK INC.2013-04-102016-04-05Us
ZyprexaTablet, coated2.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated20 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet10 mg/1OralEli Lilly and Company1996-10-01Not applicableUs
ZyprexaTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-07-12Not applicableUs
ZyprexaTablet, coated2.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated10 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.1996-10-01Not applicableUs
ZyprexaTablet5 mg/1OralRebel Distributors Corp1996-10-01Not applicableUs
ZyprexaTablet, coated20 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated7.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet2.5 mg/1OralEli Lilly and Company1997-06-23Not applicableUs
ZyprexaTablet2.5 mg/1OralPhysicians Total Care, Inc.2003-08-20Not applicableUs
ZyprexaTablet10 mg/1OralDispensing Solutions, Inc.1996-10-01Not applicableUs
ZyprexaTablet, coated10 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
ZyprexaTablet, coated15 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet5 mg/1OralREMEDYREPACK INC.2013-04-102016-04-05Us
ZyprexaTablet, coated5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated2.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet15 mg/1OralEli Lilly and Company2000-01-10Not applicableUs
ZyprexaTablet, coated2.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated15 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet2.5 mg/1Oralbryant ranch prepack1997-06-23Not applicableUs
ZyprexaTablet10 mg/1OralRebel Distributors Corp1996-10-01Not applicableUs
ZyprexaInjection, powder, for solution10 mgIntramuscularEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated10 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet5 mg/1OralEli Lilly and Company1996-10-01Not applicableUs
ZyprexaTablet7.5 mg/1OralPhysicians Total Care, Inc.2005-06-14Not applicableUs
ZyprexaTablet15 mg/1OralDispensing Solutions, Inc.2000-01-10Not applicableUs
ZyprexaTablet, coated10 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet2.5 mg/1OralH.J. Harkins Company, Inc.1997-06-23Not applicableUs
ZyprexaTablet, coated20 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet15 mg/1OralREMEDYREPACK INC.2013-05-142016-04-05Us
ZyprexaTablet, coated15 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet20 mg/1OralEli Lilly and Company2001-03-01Not applicableUs
ZyprexaTablet, coated5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated7.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated20 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet2.5 mg/1OralDispensing Solutions, Inc.1997-06-23Not applicableUs
ZyprexaTablet20 mg/1OralRebel Distributors Corp2001-03-01Not applicableUs
ZyprexaInjection, powder, for solution10 mgIntramuscularEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet, coated15 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet7.5 mg/1OralEli Lilly and Company1996-10-01Not applicableUs
ZyprexaTablet5 mg/1OralCardinal Health1996-10-01Not applicableUs
ZyprexaTablet, coated7.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaTablet10 mg/1OralPhysicians Total Care, Inc.2003-06-20Not applicableUs
ZyprexaTablet, coated2.5 mgOralEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexa -2.5mgTablet2.5 mgOralEli Lilly Canada Inc1997-12-08Not applicableCanada
Zyprexa -7.5mgTablet7.5 mgOralEli Lilly Canada Inc1996-11-04Not applicableCanada
Zyprexa - 10mgTablet10 mgOralEli Lilly Canada Inc1996-11-14Not applicableCanada
Zyprexa - 5mgTablet5 mgOralEli Lilly Canada Inc1996-11-14Not applicableCanada
Zyprexa 15mgTablet15 mgOralEli Lilly Canada Inc2002-06-24Not applicableCanada
Zyprexa 20mgTablet20 mgOralEli Lilly Canada Inc2007-04-30Not applicableCanada
Zyprexa IntramuscularInjection, powder, for solution10 mg/2mLIntramuscularEli Lilly and Company2004-04-01Not applicableUs
Zyprexa IntramuscularInjection, powder, for solution10 mg/2mLIntramuscularTYA Pharmaceuticals2004-04-01Not applicableUs
Zyprexa IntramuscularPowder, for solution10 mgIntramuscularEli Lilly Canada Inc2004-01-12Not applicableCanada
Zyprexa RelprevvKitIntramuscularEli Lilly and Company2009-12-11Not applicableUs
Zyprexa RelprevvKitIntramuscularEli Lilly and Company2009-12-11Not applicableUs
Zyprexa RelprevvKitIntramuscularEli Lilly and Company2009-12-11Not applicableUs
Zyprexa VelotabTablet, orally disintegrating20 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating5 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating20 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating5 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating20 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating5 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating5 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating10 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating10 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating5 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating10 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating10 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating15 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating15 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating10 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating15 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating15 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating20 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating20 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabTablet, orally disintegrating15 mgOralEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa ZydisTablet, orally disintegrating5 mg/1OralEli Lilly and Company2000-06-01Not applicableUs
Zyprexa ZydisTablet, orally disintegrating15 mgOralEli Lilly Canada Inc2004-01-09Not applicableCanada
Zyprexa ZydisTablet, orally disintegrating10 mg/1OralEli Lilly and Company2000-06-01Not applicableUs
Zyprexa ZydisTablet, orally disintegrating20 mgOralEli Lilly Canada Inc2007-01-02Not applicableCanada
Zyprexa ZydisTablet, orally disintegrating5 mgOralEli Lilly Canada Inc2001-03-06Not applicableCanada
Zyprexa ZydisTablet, orally disintegrating10 mg/1OralCardinal Health2000-06-01Not applicableUs
Zyprexa ZydisTablet, orally disintegrating15 mg/1OralEli Lilly and Company2001-09-01Not applicableUs
Zyprexa ZydisTablet, orally disintegrating10 mgOralEli Lilly Canada Inc2001-03-15Not applicableCanada
Zyprexa ZydisTablet, orally disintegrating5 mg/1OralCardinal Health2000-06-01Not applicableUs
Zyprexa ZydisTablet, orally disintegrating20 mg/1OralEli Lilly and Company2001-09-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olanzapineTablet20.0 mgOralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapineTablet5.0 mgOralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapineTablet7.5 mgOralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapineTablet10.0 mgOralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapineTablet2.5 mgOralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapineTablet15.0 mgOralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating20 mgOralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating5 mgOralApotex Inc2011-11-16Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating10 mgOralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTTablet, orally disintegrating15 mgOralApotex Inc2011-08-08Not applicableCanada
OlanzapineTablet, orally disintegrating15 mg/1OralAv Pak2014-04-17Not applicableUs
OlanzapineTablet20 mg/1OralLucid Pharma Llc2014-09-26Not applicableUs
OlanzapineTablet, film coated20 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralCardinal Health2012-02-17Not applicableUs
OlanzapineTablet, film coated10 mg/1OralAmerican Health Packaging2014-05-01Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralApotex Corp.2012-04-23Not applicableUs
OlanzapineTablet20 mg/1OralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
OlanzapineTablet10 mg/1OralCitron Pharma LLC2012-04-232015-12-29Us
OlanzapineTablet10 mg/1OralMylan Institutional Inc.2016-04-27Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralREMEDYREPACK INC.2015-10-19Not applicableUs
OlanzapineTablet5 mg/1OralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
OlanzapineTablet, film coated15 mg/1OralAv Pak2016-10-12Not applicableUs
OlanzapineTablet, film coated10 mg/1OralProficient Rx LP2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
OlanzapineTablet2.5 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet20 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineInjection, powder, for solution10 mg/2mLIntramuscularSandoz Inc2011-10-24Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
OlanzapineTablet15 mg/1OralREMEDYREPACK INC.2014-02-06Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralTeva Pharmaceuticals Usa, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
OlanzapineTablet10 mg/1OralAscend Laboratories, LLC2012-01-01Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralCardinal Health2012-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
OlanzapineTablet, film coated5 mg/1OralMylan Institutional Inc.2012-06-082015-12-29Us
OlanzapineTablet, orally disintegrating5 mg/1OralAurobindo Pharma Limited2014-05-15Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralAmerican Health Packaging2016-01-01Not applicableUs
OlanzapineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-05-25Not applicableUs
OlanzapineTablet10 mg/1OralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated10 mg/1OralA S Medication Solutions2012-04-23Not applicableUs
OlanzapineTablet10 mg/1OralTYA Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralPrasco Laboratories2011-10-25Not applicableUs
OlanzapineTablet, film coated20 mg/1OralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
OlanzapineTablet10 mg/1OralA S Medication Solutions2012-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
OlanzapineTablet20 mg/1OralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
OlanzapineTablet7.5 mg/1OralAjanta Pharma Limited2016-08-22Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralProficient Rx LP2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-02-17Not applicableUs
OlanzapineTablet15 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralPrasco Laboratories2014-05-15Not applicableUs
OlanzapineTablet, film coated10 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet10 mg/1OralREMEDYREPACK INC.2013-03-28Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralDr.Reddy's Laboratories Limited2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
OlanzapineTablet, film coated15 mg/1OralDispensing Solutions, Inc.2011-10-24Not applicableUs
OlanzapineTablet7.5 mg/1OralAurobindo Pharma Limited2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralApotex Corp.2011-10-24Not applicableUs
OlanzapineTablet, film coated10 mg/1OralRebel Distributors Corp2011-10-24Not applicableUs
OlanzapineTablet, film coated5 mg/1OralCardinal Health2012-04-23Not applicableUs
OlanzapineTablet, film coated15 mg/1OralAmerican Health Packaging2012-02-01Not applicableUs
OlanzapineTablet, film coated10 mg/1OralClinical Solutions Wholesale2011-10-24Not applicableUs
OlanzapineTablet, film coated20 mg/1OralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
OlanzapineTablet7.5 mg/1OralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
OlanzapineTablet2.5 mg/1OralCitron Pharma LLC2012-04-232015-12-29Us
OlanzapineTablet, film coated7.5 mg/1OralREMEDYREPACK INC.2016-01-07Not applicableUs
OlanzapineTablet, film coated20 mg/1OralREMEDYREPACK INC.2014-08-07Not applicableUs
OlanzapineTablet, film coated5 mg/1OralAv Pak2016-10-12Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
OlanzapineTablet, film coated10 mg/1OralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
OlanzapineInjection, powder, lyophilized, for solution10 mg/2mLIntramuscularTYA Pharmaceuticals2012-06-27Not applicableUs
OlanzapineTablet5 mg/1OralREMEDYREPACK INC.2016-11-30Not applicableUs
OlanzapineTablet7.5 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
OlanzapineTablet5 mg/1OralREMEDYREPACK INC.2013-04-012016-10-13Us
OlanzapineTablet7.5 mg/1OralLucid Pharma Llc2014-09-26Not applicableUs
OlanzapineTablet, film coated15 mg/1OralTeva Pharmaceuticals Usa, Inc.2011-10-24Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralAv Pak2014-04-17Not applicableUs
OlanzapineTablet, film coated15 mg/1OralPhysicians Total Care, Inc.2012-07-02Not applicableUs
OlanzapineTablet, film coated5 mg/1OralREMEDYREPACK INC.2013-04-22Not applicableUs
OlanzapineTablet, film coated10 mg/1OralClinical Solutions Wholesale, Llc2012-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralDispensing Solutions, Inc.2011-10-24Not applicableUs
OlanzapineTablet, film coated15 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
OlanzapineTablet, film coated10 mg/1OralApotex Corp.2012-04-23Not applicableUs
OlanzapineTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-10-24Not applicableUs
OlanzapineTablet15 mg/1OralCitron Pharma LLC2012-04-232015-12-29Us
OlanzapineTablet15 mg/1OralMylan Institutional Inc.2016-04-27Not applicableUs
OlanzapineTablet20 mg/1OralREMEDYREPACK INC.2015-10-19Not applicableUs
OlanzapineTablet7.5 mg/1OralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
OlanzapineTablet, film coated20 mg/1OralAv Pak2016-10-12Not applicableUs
OlanzapineTablet, film coated20 mg/1OralProficient Rx LP2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
OlanzapineTablet5 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralPrasco Laboratories2014-05-15Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
OlanzapineTablet, film coated10 mg/1OralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
OlanzapineTablet, film coated5 mg/1OralREMEDYREPACK INC.2014-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralTeva Pharmaceuticals Usa, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
OlanzapineTablet15 mg/1OralAscend Laboratories, LLC2012-01-01Not applicableUs
OlanzapineTablet, film coated10 mg/1OralCardinal Health2012-04-23Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
OlanzapineTablet, film coated10 mg/1OralMylan Institutional Inc.2012-06-082015-12-29Us
OlanzapineTablet, orally disintegrating10 mg/1OralAurobindo Pharma Limited2014-05-15Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralAmerican Health Packaging2016-01-01Not applicableUs
OlanzapineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-06-03Not applicableUs
OlanzapineTablet15 mg/1OralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
OlanzapineTablet15 mg/1OralTYA Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralPrasco Laboratories2011-10-25Not applicableUs
OlanzapineTablet, film coated15 mg/1OralDr.Reddy's laboratories Ltd.2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralDispensing Solutions, Inc.2011-10-24Not applicableUs
OlanzapineTablet10 mg/1OralAurobindo Pharma Limited2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralApotex Corp.2011-10-24Not applicableUs
OlanzapineTablet, film coated20 mg/1OralRebel Distributors Corp2011-10-24Not applicableUs
OlanzapineTablet, film coated15 mg/1OralREMEDYREPACK INC.2016-05-16Not applicableUs
OlanzapineTablet2.5 mg/1OralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralAvera Mc Kennan Hospital2015-09-02Not applicableUs
OlanzapineTablet10 mg/1OralAjanta Pharma Limited2016-08-22Not applicableUs
OlanzapineTablet, film coated2.5 mg/1Oralbryant ranch prepack2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-02-17Not applicableUs
OlanzapineTablet20 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet2.5 mg/1OralAscend Laboratories, LLC2012-01-01Not applicableUs
OlanzapineTablet, film coated5 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet5 mg/1OralREMEDYREPACK INC.2013-04-01Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralAv Pak2014-04-17Not applicableUs
OlanzapineTablet10 mg/1OralLucid Pharma Llc2014-09-26Not applicableUs
OlanzapineInjection, powder, lyophilized, for solution10 mg/2mLIntramuscularAmerican Regent, Inc.2012-06-27Not applicableUs
OlanzapineTablet, film coated10 mg/1OralCardinal Health2012-04-23Not applicableUs
OlanzapineTablet, film coated20 mg/1OralAmerican Health Packaging2012-02-01Not applicableUs
OlanzapineTablet, film coated15 mg/1OralClinical Solutions Wholesale2011-10-24Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralApotex Corp.2012-04-23Not applicableUs
OlanzapineTablet10 mg/1OralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
OlanzapineTablet5 mg/1OralCitron Pharma LLC2012-04-232015-12-29Us
OlanzapineTablet2.5 mg/1OralMylan Institutional Inc.2016-05-10Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralREMEDYREPACK INC.2015-05-26Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2012-12-13Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralAv Pak2016-10-12Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
OlanzapineTablet, film coated15 mg/1OralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
OlanzapineInjection, powder, for solution10 mg/2mLIntramuscularTYA Pharmaceuticals2011-10-24Not applicableUs
OlanzapineTablet10 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, film coated15 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
OlanzapineTablet, film coated5 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet10 mg/1OralREMEDYREPACK INC.2013-03-292016-10-13Us
OlanzapineTablet, film coated7.5 mg/1OralPhysicians Total Care, Inc.2012-08-22Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
OlanzapineTablet, film coated20 mg/1OralClinical Solutions Wholesale2011-10-24Not applicableUs
OlanzapineTablet, film coated10 mg/1OralDispensing Solutions, Inc.2011-10-24Not applicableUs
OlanzapineTablet2.5 mg/1OralAurobindo Pharma Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated15 mg/1OralApotex Corp.2012-04-23Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralRebel Distributors Corp2011-10-24Not applicableUs
OlanzapineTablet20 mg/1OralCitron Pharma LLC2012-04-232015-12-29Us
OlanzapineTablet20 mg/1OralMylan Institutional Inc.2016-04-28Not applicableUs
OlanzapineTablet, film coated20 mg/1OralREMEDYREPACK INC.2015-11-17Not applicableUs
OlanzapineTablet10 mg/1OralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
OlanzapineTablet2.5 mg/1OralAjanta Pharma Limited2016-08-22Not applicableUs
OlanzapineTablet, film coated5 mg/1OralProficient Rx LP2014-08-22Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
OlanzapineTablet7.5 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralPrasco Laboratories2014-05-15Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
OlanzapineTablet2.5 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
OlanzapineTablet, film coated5 mg/1OralREMEDYREPACK INC.2013-05-012016-10-13Us
OlanzapineTablet2.5 mg/1OralLucid Pharma Llc2014-09-26Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralTeva Pharmaceuticals Usa, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
OlanzapineTablet20 mg/1OralAscend Laboratories, LLC2012-01-01Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralClinical Solutions Wholesale2011-10-24Not applicableUs
OlanzapineTablet, film coated10 mg/1OralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
OlanzapineTablet2.5 mg/1OralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated15 mg/1OralMylan Institutional Inc.2012-06-082015-12-29Us
OlanzapineTablet, orally disintegrating15 mg/1OralAurobindo Pharma Limited2014-05-15Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralAmerican Health Packaging2016-01-01Not applicableUs
OlanzapineTablet, film coated10 mg/1OralProficient Rx LP2014-08-22Not applicableUs
OlanzapineTablet20 mg/1OralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralTYA Pharmaceuticals2012-02-28Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-01-212016-04-05Us
OlanzapineTablet, film coated20 mg/1OralDr.Reddy's laboratories Ltd.2012-04-23Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-06-05Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralAvera Mc Kennan Hospital2015-04-22Not applicableUs
OlanzapineTablet15 mg/1OralAurobindo Pharma Limited2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralApotex Corp.2011-10-24Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralRebel Distributors Corp2011-10-24Not applicableUs
OlanzapineTablet, film coated5 mg/1OralREMEDYREPACK INC.2016-05-17Not applicableUs
OlanzapineTablet5 mg/1OralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
OlanzapineTablet15 mg/1OralAjanta Pharma Limited2016-08-22Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralTYA Pharmaceuticals2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-01-24Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralPrasco Laboratories2011-10-25Not applicableUs
OlanzapineTablet5 mg/1OralAscend Laboratories, LLC2012-01-01Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralAv Pak2014-04-17Not applicableUs
OlanzapineTablet15 mg/1OralLucid Pharma Llc2014-09-26Not applicableUs
OlanzapineTablet, film coated15 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralCardinal Health2012-02-17Not applicableUs
OlanzapineTablet, film coated5 mg/1OralAmerican Health Packaging2014-05-01Not applicableUs
OlanzapineTablet, film coated15 mg/1OralREMEDYREPACK INC.2014-08-07Not applicableUs
OlanzapineTablet, film coated5 mg/1OralApotex Corp.2012-04-23Not applicableUs
OlanzapineTablet15 mg/1OralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
OlanzapineTablet7.5 mg/1OralCitron Pharma LLC2012-04-232015-12-29Us
OlanzapineTablet5 mg/1OralMylan Institutional Inc.2016-04-26Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-08-06Not applicableUs
OlanzapineTablet2.5 mg/1OralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
OlanzapineTablet, film coated10 mg/1OralAv Pak2016-10-12Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
OlanzapineTablet, film coated20 mg/1OralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
OlanzapineTablet, film coated5 mg/1OralTYA Pharmaceuticals2011-10-24Not applicableUs
OlanzapineTablet15 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineInjection, powder, for solution10 mg/2mLIntramuscularSandoz Inc2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
OlanzapineTablet10 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating15 mg/1OralPrasco Laboratories2014-05-15Not applicableUs
OlanzapineTablet, film coated10 mg/1OralMajor Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-01-04Not applicableUs
OlanzapineTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2012-08-22Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralDispensing Solutions, Inc.2011-10-24Not applicableUs
OlanzapineTablet5 mg/1OralAurobindo Pharma Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated20 mg/1OralApotex Corp.2012-04-23Not applicableUs
OlanzapineTablet, film coated5 mg/1OralRebel Distributors Corp2011-10-24Not applicableUs
OlanzapineTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-04-23Not applicableUs
OlanzapineTablet, film coated20 mg/1OralREMEDYREPACK INC.2015-11-20Not applicableUs
OlanzapineTablet15 mg/1OralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
OlanzapineTablet5 mg/1OralAjanta Pharma Limited2016-08-22Not applicableUs
OlanzapineTablet, film coated10 mg/1OralProficient Rx LP2012-04-23Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralAv Pak2016-10-12Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
OlanzapineTablet, film coated7.5 mg/1OralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralTYA Pharmaceuticals2012-02-28Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
OlanzapineTablet5 mg/1OralPrasco Laboratories2012-04-23Not applicableUs
OlanzapineTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
OlanzapineTablet10 mg/1OralREMEDYREPACK INC.2013-04-012016-10-13Us
OlanzapineTablet5 mg/1OralLucid Pharma Llc2014-09-26Not applicableUs
OlanzapineTablet, film coated10 mg/1OralTeva Pharmaceuticals Usa, Inc.2011-10-24Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralCardinal Health2011-10-24Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralAmerican Health Packaging2012-05-01Not applicableUs
OlanzapineTablet, film coated5 mg/1OralClinical Solutions Wholesale2011-10-24Not applicableUs
OlanzapineTablet, film coated15 mg/1OralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
OlanzapineTablet5 mg/1OralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
OlanzapineTablet, film coated20 mg/1OralMylan Institutional Inc.2012-06-082015-12-29Us
OlanzapineTablet, orally disintegrating20 mg/1OralAurobindo Pharma Limited2014-05-15Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralAmerican Health Packaging2016-01-01Not applicableUs
OlanzapineTablet10 mg/1OralREMEDYREPACK INC.2014-02-03Not applicableUs
OlanzapineTablet, orally disintegrating5 mg/1OralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
OlanzapineTablet, film coated5 mg/1OralCardinal Health2012-04-23Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
OlanzapineTablet, film coated2.5 mg/1OralMylan Institutional Inc.2012-06-082015-12-29Us
OlanzapineTablet20 mg/1OralAurobindo Pharma Limited2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralApotex Corp.2011-10-24Not applicableUs
OlanzapineTablet, film coated5 mg/1OralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
OlanzapineTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-05-17Not applicableUs
OlanzapineTablet7.5 mg/1OralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
OlanzapineTablet20 mg/1OralAjanta Pharma Limited2016-08-22Not applicableUs
OlanzapineTablet5 mg/1OralTYA Pharmaceuticals2012-04-23Not applicableUs
OlanzapineTablet, orally disintegrating20 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-01-24Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralPrasco Laboratories2011-10-25Not applicableUs
OlanzapineTablet7.5 mg/1OralAscend Laboratories, LLC2012-01-02Not applicableUs
OlanzapineTablet, orally disintegrating10 mg/1OralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapine ApotexTablet, orally disintegrating10 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating10 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating20 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated10 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating10 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated7.5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating15 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated7.5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated2.5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated10 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating20 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated10 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, film coated5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexTablet, orally disintegrating5 mgOralApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine GlenmarkTablet7.5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet15 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet10 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet7.5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet2.5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet20 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet10 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet7.5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet2.5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet20 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet15 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet10 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet2.5 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet15 mgOralGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating10 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating15 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating5 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating10 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating20 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating5 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating15 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating20 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating10 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating15 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating5 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeTablet, orally disintegrating20 mgOralGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine TevaTablet, film coated20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated2.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated2.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated2.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated2.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated2.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated2.5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating20 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating15 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating5 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, orally disintegrating10 mgOralTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaTablet, film coated7.5 mgOralTeva Pharma2007-12-12Not applicableEu
OlazaxTablet10 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet15 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet5 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet20 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet7.5 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
Olazax DisperziTablet, orally disintegrating7.5 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziTablet, orally disintegrating10 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziTablet, orally disintegrating15 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziTablet, orally disintegrating20 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziTablet, orally disintegrating5 mgOralGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
ZalastaTablet2.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating10 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating7.5 mgOralKrka2007-09-27Not applicableEu
ZalastaTablet, orally disintegrating20 mgOralKrka2007-09-27Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Olanzapine NeopharmaTablet, coated10 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated2.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated7.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated10 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated2.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated7.5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated15 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated10 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated15 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaTablet, coated5 mgOralCipla (Eu) Limited2007-11-14Not applicableEu
International Brands
NameCompany
AedonG.L. Pharma
AmulsinSanitas
ApiscoLKM
ApsicoLKM
ArkolamylMylan
CaprilonLavipharm
CO OlanzapineCobalt
DeprexSquare
DominazolStein
DopinDaksh
EgolanzaEGIS
ElynzaElynza
FrenialBiogen
Jolyon-MDLupin
KozylexQuisisana
LanopinMolekule
LanzapinBiogened
LanzepRenata
LapenzaSmart Intermed
LapozanMedochemie
LazapixPortfarma
Brand mixtures
NameLabellerIngredients
Olanzapine and FluoxetineSandoz Inc
SymbyaxEli Lilly and Company
Salts
Name/CASStructureProperties
Olanzapine pamoate
221373-18-8
Thumb
  • InChI Key: ZIMCQJVMPKQQPB-UHFFFAOYSA-N
  • Monoisotopic Mass: 718.246120754
  • Average Mass: 718.83
DBSALT001064
Categories
UNIIN7U69T4SZR
CAS number132539-06-1
WeightAverage: 312.432
Monoisotopic: 312.14086735
Chemical FormulaC17H20N4S
InChI KeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
IUPAC Name
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Pharmacology
IndicationFor the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.
Structured Indications
PharmacodynamicsOlanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.
Mechanism of actionOlanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(2) dopamine receptorProteinyes
antagonist
agonist
HumanP14416 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(1B) dopamine receptorProteinunknown
antagonist
HumanP21918 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
antagonist
HumanP28222 details
5-hydroxytryptamine receptor 1DProteinunknown
antagonist
HumanP28221 details
5-hydroxytryptamine receptor 1EProteinunknown
antagonist
HumanP28566 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 3AProteinunknown
antagonist
HumanP46098 details
5-hydroxytryptamine receptor 6Proteinunknown
antagonist
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
5-hydroxytryptamine receptor 2BProteinunknown
antagonist
HumanP41595 details
5-hydroxytryptamine receptor 5AProteinunknown
antagonist
HumanP47898 details
D(1) dopamine receptorProtein groupunknown
antagonist
Humannot applicabledetails
Histamine H2 receptorProteinunknown
antagonist
HumanP25021 details
Histamine H4 receptorProteinunknown
antagonist
HumanQ9H3N8 details
GABA-A receptor (anion channel)Protein groupunknownNot AvailableHumannot applicabledetails
Beta adrenergic receptorProtein groupunknownNot AvailableHumannot applicabledetails
D(2L) dopamine receptorProteinunknownNot AvailableHumannot applicabledetails
D(2S) dopamine receptorProteinunknownNot AvailableHumannot applicabledetails
Related Articles
AbsorptionWell absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.
Volume of distribution
  • 1000 L
Protein binding93%
Metabolism

Hepatic

SubstrateEnzymesProduct
Olanzapine
7-hydroxyolanzapineDetails
Olanzapine
4'-N-desmethylolanzapineDetails
Olanzapine
2-hydroxymethylolanzapineDetails
Route of eliminationIt is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.
Half life21 to 54 hours
Clearance
  • 12 to 47 L/h
ToxicitySymptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableCC Allele (homozygous)Associated with the ability to ameliorate impaired attention in patients with schizophrenia.20533011
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Olanzapine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineOlanzapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineOlanzapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Olanzapine.Experimental
AbirateroneThe serum concentration of Olanzapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Olanzapine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Olanzapine can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine.Withdrawn
adipiplonThe risk or severity of adverse effects can be increased when Olanzapine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Olanzapine can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Agomelatine.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Olanzapine.Experimental
AlbendazoleThe serum concentration of Olanzapine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Olanzapine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Olanzapine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Olanzapine can be increased when it is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alprazolam.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Olanzapine.Approved
Aminohippuric acidThe serum concentration of Olanzapine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneOlanzapine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Olanzapine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Olanzapine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amperozide.Experimental
AmphetamineOlanzapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Olanzapine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Olanzapine can be increased when it is combined with Amsacrine.Approved
AnagrelideOlanzapine may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Olanzapine.Approved, Investigational
Arsenic trioxideOlanzapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherOlanzapine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Articaine.Approved
AsenapineOlanzapine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Olanzapine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Olanzapine.Approved, Investigational
AtenololThe serum concentration of Olanzapine can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Olanzapine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Olanzapine can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Azaperone.Vet Approved
AzelastineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Olanzapine can be increased when it is combined with Azelastine.Approved
AzithromycinOlanzapine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Olanzapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Olanzapine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital.Illicit
BedaquilineOlanzapine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Olanzapine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Olanzapine can be increased when it is combined with Benzocaine.Approved
BenzphetamineOlanzapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Olanzapine is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Olanzapine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Olanzapine can be decreased when combined with Betaxolol.Approved
BiperidenThe serum concentration of Olanzapine can be increased when it is combined with Biperiden.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine.Investigational
BortezomibThe metabolism of Olanzapine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Olanzapine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Olanzapine.Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olanzapine.Approved, Investigational
BuprenorphineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Olanzapine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Olanzapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Olanzapine can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Olanzapine.Approved
CaffeineThe serum concentration of Olanzapine can be increased when it is combined with Caffeine.Approved
CamazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Camazepam.Approved, Illicit
CanagliflozinThe serum concentration of Olanzapine can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Olanzapine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Olanzapine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Olanzapine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Olanzapine.Withdrawn
CarvedilolThe serum concentration of Olanzapine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Olanzapine can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Olanzapine.Experimental
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Olanzapine.Approved
CefpodoximeOlanzapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeOlanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CelecoxibThe metabolism of Olanzapine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibOlanzapine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chloroprocaine.Approved
ChloroquineOlanzapine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorphenamine.Approved
ChlorphentermineOlanzapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineOlanzapine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Olanzapine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Olanzapine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Olanzapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Olanzapine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Olanzapine can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Olanzapine.Experimental
CilazaprilThe serum concentration of Olanzapine can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Olanzapine.Approved
CimetidineThe serum concentration of Olanzapine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Olanzapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinOlanzapine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideOlanzapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramOlanzapine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinOlanzapine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Olanzapine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clidinium.Approved
ClobazamThe metabolism of Olanzapine can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Olanzapine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with clomethiazole.Investigational
ClomipramineThe serum concentration of Olanzapine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe serum concentration of Olanzapine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineOlanzapine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Olanzapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Olanzapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Olanzapine.Approved, Illicit
ColchicineThe serum concentration of Olanzapine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Olanzapine can be increased when it is combined with Colforsin.Experimental
CrizotinibOlanzapine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Olanzapine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Olanzapine can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Olanzapine.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Olanzapine.Approved
DaclatasvirThe serum concentration of Olanzapine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Olanzapine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olanzapine.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Olanzapine.Investigational
DarifenacinThe metabolism of Olanzapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Olanzapine can be increased when it is combined with Darunavir.Approved
DasatinibOlanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Olanzapine can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Olanzapine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Delorazepam.Approved, Illicit
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Olanzapine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Olanzapine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Desflurane.Approved
DesipramineThe serum concentration of Olanzapine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Olanzapine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Olanzapine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Olanzapine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateOlanzapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineOlanzapine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Olanzapine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Olanzapine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylpropionOlanzapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Olanzapine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Olanzapine can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Olanzapine can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Olanzapine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Olanzapine can be increased when it is combined with Dipyridamole.Approved
DisopyramideOlanzapine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideOlanzapine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronOlanzapine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneOlanzapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Doramectin.Vet Approved
DoxazosinThe serum concentration of Olanzapine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Olanzapine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Olanzapine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Olanzapine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Illicit
DronedaroneOlanzapine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Olanzapine.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Olanzapine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Olanzapine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Olanzapine is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Olanzapine can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine.Approved, Investigational
EliglustatOlanzapine may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.Approved
EnalaprilThe serum concentration of Olanzapine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Olanzapine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Olanzapine can be increased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.Approved
ErgonovineThe serum concentration of Olanzapine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Olanzapine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
ErythromycinOlanzapine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramOlanzapine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Estazolam.Approved, Illicit
EstramustineThe serum concentration of Olanzapine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Olanzapine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Olanzapine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone.Approved
EthanolOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olanzapine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Olanzapine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Olanzapine.Approved
EtoposideThe serum concentration of Olanzapine can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Olanzapine can be increased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Olanzapine.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Felbamate.Approved
FelodipineThe serum concentration of Olanzapine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe serum concentration of Olanzapine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseOlanzapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateOlanzapine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateOlanzapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.Approved
FexofenadineThe serum concentration of Olanzapine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Olanzapine can be increased when it is combined with Fidaxomicin.Approved
FlecainideOlanzapine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flibanserin.Approved
FluconazoleThe serum concentration of Olanzapine can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fludiazepam.Approved, Illicit
FlumazenilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flumazenil.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineOlanzapine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolOlanzapine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Olanzapine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Olanzapine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Olanzapine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olanzapine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Olanzapine is combined with gabapentin enacarbil.Approved
Gadobenic acidOlanzapine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Olanzapine.Approved, Investigational
GemifloxacinOlanzapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Olanzapine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Olanzapine.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Olanzapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Olanzapine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Olanzapine can be increased when it is combined with Glycerol.Experimental
GoserelinOlanzapine may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Olanzapine can be increased when it is combined with Gramicidin D.Approved
GranisetronOlanzapine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe serum concentration of Olanzapine can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Olanzapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolOlanzapine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Olanzapine.Approved
HydrocodoneOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Olanzapine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine.Approved, Illicit
Hydroxyamphetamine hydrobromideOlanzapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
IbutilideOlanzapine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Olanzapine can be increased when it is combined with Idelalisib.Approved
IloperidoneOlanzapine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Olanzapine can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Olanzapine can be increased when it is combined with Imipramine.Approved
IndalpineIndalpine may increase the serotonergic activities of Olanzapine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Olanzapine.Approved
IndomethacinThe serum concentration of Olanzapine can be increased when it is combined with Indomethacin.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Olanzapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Olanzapine.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Olanzapine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olanzapine.Withdrawn
IronOlanzapine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranOlanzapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateOlanzapine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe serum concentration of Olanzapine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olanzapine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Olanzapine can be decreased when combined with Isoniazid.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Olanzapine.Approved, Investigational
IvacaftorThe serum concentration of Olanzapine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Olanzapine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Olanzapine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Olanzapine.Approved, Investigational
KetoconazoleThe serum concentration of Olanzapine can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineLamotrigine may increase the sedative activities of Olanzapine.Approved, Investigational
LansoprazoleThe serum concentration of Olanzapine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Olanzapine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Olanzapine.Approved
LenvatinibOlanzapine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideOlanzapine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Olanzapine.Approved
LevofloxacinOlanzapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Olanzapine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Olanzapine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Olanzapine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine.Approved, Investigational
LiothyronineThe serum concentration of Olanzapine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Olanzapine can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine.Approved
LisdexamfetamineOlanzapine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Olanzapine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Olanzapine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Olanzapine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Olanzapine can be increased when it is combined with Loperamide.Approved
LopinavirOlanzapine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Olanzapine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lorazepam.Approved
LorcaserinThe metabolism of Olanzapine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Olanzapine can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Olanzapine can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Olanzapine is combined with Lu AA21004.Investigational
LumacaftorThe serum concentration of Olanzapine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineOlanzapine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Vet Approved
MaprotilineThe serum concentration of Olanzapine can be increased when it is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Olanzapine.Withdrawn
MebendazoleThe serum concentration of Olanzapine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Olanzapine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Olanzapine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Olanzapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Melperone.Approved
MephedroneOlanzapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineOlanzapine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Olanzapine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineOlanzapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.Approved
MethadoneOlanzapine may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineOlanzapine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methohexital.Approved
MethotrimeprazineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Olanzapine.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Olanzapine.Approved, Investigational
MetyrosineOlanzapine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Olanzapine can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Olanzapine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Olanzapine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Olanzapine.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Olanzapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Olanzapine.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Olanzapine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Olanzapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
MirabegronThe metabolism of Olanzapine can be decreased when combined with Mirabegron.Approved
MirtazapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Olanzapine.Approved, Investigational
MitomycinThe serum concentration of Olanzapine can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Olanzapine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAOlanzapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Olanzapine.Approved, Withdrawn
MorphineThe serum concentration of Olanzapine can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinOlanzapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine.Approved
NaltrexoneThe serum concentration of Olanzapine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine.Approved, Investigational
NaringeninThe serum concentration of Olanzapine can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Olanzapine.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Olanzapine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine.Approved
NeostigmineThe serum concentration of Olanzapine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetazepideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Netazepide.Investigational
NevirapineThe metabolism of Olanzapine can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Olanzapine.Withdrawn
NicardipineThe serum concentration of Olanzapine can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Olanzapine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
NisoldipineThe serum concentration of Olanzapine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Olanzapine can be increased when it is combined with Nitrendipine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrous oxide.Approved, Vet Approved
NorethisteroneThe serum concentration of Olanzapine can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Olanzapine.Withdrawn
OfloxacinOlanzapine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Olanzapine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOlanzapine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Olanzapine is combined with Opium.Approved, Illicit
OrphenadrineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Olanzapine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxymorphone.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Olanzapine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Olanzapine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneOlanzapine may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Olanzapine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Olanzapine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Olanzapine can be increased when it is combined with Pantoprazole.Approved
ParaldehydeOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Olanzapine.Approved
ParoxetineThe metabolism of Olanzapine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Olanzapine.Approved
Peginterferon alfa-2bThe serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineOlanzapine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olanzapine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine.Investigational
PerflutrenOlanzapine may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe serum concentration of Olanzapine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olanzapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine.Approved
Pf 00477736The risk or severity of adverse effects can be increased when Olanzapine is combined with Pf 00477736.Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Olanzapine.Approved, Withdrawn
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Olanzapine.Withdrawn
PhenobarbitalThe metabolism of Olanzapine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Olanzapine.Withdrawn
PhentermineOlanzapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Phenytoin.Approved, Vet Approved
PimozideOlanzapine may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Olanzapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pirenzepine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Olanzapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Olanzapine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Olanzapine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Olanzapine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Olanzapine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Olanzapine.Approved, Investigational, Vet Approved
PramipexoleOlanzapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Olanzapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Olanzapine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Olanzapine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Olanzapine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olanzapine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prilocaine.Approved
PrimaquineOlanzapine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Olanzapine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Olanzapine can be increased when it is combined with Probenecid.Approved
ProcainamideOlanzapine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olanzapine.Approved, Vet Approved
ProgesteroneThe serum concentration of Olanzapine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineOlanzapine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Olanzapine can be increased when it is combined with Promethazine.Approved
PropafenoneOlanzapine may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Proparacaine.Approved, Vet Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Olanzapine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Olanzapine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Olanzapine can be increased when it is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Olanzapine is combined with PSD502.Investigational
PseudoephedrineOlanzapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Olanzapine can be increased when it is combined with Quercetin.Experimental
QuetiapineOlanzapine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Olanzapine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Olanzapine.Approved
QuinidineOlanzapine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineOlanzapine may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Olanzapine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Olanzapine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine.Approved
ReboxetineThe serum concentration of Olanzapine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Olanzapine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine.Approved, Investigational
ReserpineThe serum concentration of Olanzapine can be decreased when it is combined with Reserpine.Approved
RifampicinThe metabolism of Olanzapine can be increased when combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Olanzapine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Olanzapine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ritanserin.Investigational
RitobegronOlanzapine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Olanzapine can be decreased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine.Approved
RolapitantThe serum concentration of Olanzapine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Romifidine.Vet Approved
RopiniroleOlanzapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olanzapine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Olanzapine.Approved, Investigational
RotigotineOlanzapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olanzapine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Olanzapine is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Olanzapine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Olanzapine is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Olanzapine.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Olanzapine.Approved
ScopolamineThe serum concentration of Olanzapine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Olanzapine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the serotonergic activities of Olanzapine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe serum concentration of Olanzapine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Olanzapine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Olanzapine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Olanzapine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
SorafenibThe serum concentration of Olanzapine can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolOlanzapine may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneThe serum concentration of Olanzapine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Olanzapine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Olanzapine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe metabolism of Olanzapine can be decreased when combined with Stiripentol.Approved
StreptozocinThe serum concentration of Olanzapine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Olanzapine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleOlanzapine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Olanzapine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Olanzapine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Olanzapine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Olanzapine.Approved, Investigational
TacrolimusThe serum concentration of Olanzapine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Olanzapine can be decreased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Olanzapine can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine.Approved
TelavancinOlanzapine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinOlanzapine may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe serum concentration of Olanzapine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.Approved
TemsirolimusThe serum concentration of Olanzapine can be increased when it is combined with Temsirolimus.Approved
TenofovirThe metabolism of Olanzapine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Olanzapine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Olanzapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Olanzapine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Olanzapine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Olanzapine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrodotoxin.Investigational
ThalidomideOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Olanzapine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Olanzapine.Investigational
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Olanzapine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Olanzapine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Olanzapine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Olanzapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiletamine.Vet Approved
TipranavirThe metabolism of Olanzapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Olanzapine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Olanzapine.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Olanzapine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Olanzapine.Approved
TolvaptanThe serum concentration of Olanzapine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Topiramate.Approved
ToremifeneOlanzapine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olanzapine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olanzapine.Approved
TrazodoneThe serum concentration of Olanzapine can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triazolam.Approved
TrifluoperazineThe serum concentration of Olanzapine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Olanzapine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Olanzapine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Olanzapine can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Olanzapine.Withdrawn
TroleandomycinThe serum concentration of Olanzapine can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Olanzapine is combined with Uc1010.Investigational
Valproic AcidThe serum concentration of Olanzapine can be decreased when it is combined with Valproic Acid.Approved, Investigational
VandetanibOlanzapine may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Olanzapine.Approved, Investigational
VemurafenibThe serum concentration of Olanzapine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Olanzapine.Approved
VerapamilThe serum concentration of Olanzapine can be decreased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Olanzapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine.Approved, Investigational
VinblastineThe serum concentration of Olanzapine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Olanzapine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Olanzapine can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Olanzapine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the serotonergic activities of Olanzapine.Withdrawn
ZiprasidoneOlanzapine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Olanzapine.Approved, Investigational
ZolpidemOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zotepine.Approved
ZuclopenthixolOlanzapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

Charles Arthur Bunnell, Samuel Dean Larsen, John Richard Nichols, Susan Marie Reutzel, Gregory Alan Stephenson, “Intermediates and process for preparing olanzapine.” U.S. Patent US6020487, issued September, 1996.

US6020487
General References
  1. de Haan L, van Amelsvoort T, Rosien K, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004 Sep;175(3):389-90. [PubMed:15322727 ]
  2. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1. [PubMed:16139813 ]
  3. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. [PubMed:16415705 ]
  4. Jakovljevic M, Sagud M, Mihaljevic-Peles A: Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May;107(5):394-6; discussion 396. [PubMed:12752037 ]
  5. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1;61(1):7-18. [PubMed:12648731 ]
External Links
ATC CodesN05AH03
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (251 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.9652
Caco-2 permeable+0.5993
P-glycoprotein substrateSubstrate0.8524
P-glycoprotein inhibitor IInhibitor0.6888
P-glycoprotein inhibitor IIInhibitor0.7204
Renal organic cation transporterInhibitor0.7715
CYP450 2C9 substrateNon-substrate0.7493
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5421
CYP450 1A2 substrateInhibitor0.6454
CYP450 2C9 inhibitorNon-inhibitor0.6914
CYP450 2D6 inhibitorInhibitor0.608
CYP450 2C19 inhibitorInhibitor0.572
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.707
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.7569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
TabletOral10.0 mg
TabletOral15.0 mg
TabletOral20.0 mg
TabletOral5.0 mg
Injection, powder, for solutionIntramuscular10 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular10 mg/2mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral20 mg/1
Tablet, orally disintegratingOral5 mg/1
CapsuleOral
Tablet, film coatedOral10 mg
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral7.5 mg
Tablet, coatedOral10 mg
Tablet, coatedOral15 mg
Tablet, coatedOral2.5 mg
Tablet, coatedOral5 mg
Tablet, coatedOral7.5 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral20 mg
Tablet, orally disintegratingOral7.5 mg
Injection, powder, for suspension, extended releaseIntramuscular210 mg
Injection, powder, for suspension, extended releaseIntramuscular300 mg
Injection, powder, for suspension, extended releaseIntramuscular405 mg
Injection, powder, for solutionIntramuscular10 mg
Tablet, coatedOral20 mg
TabletOral2.5 mg
TabletOral7.5 mg
TabletOral10 mg
TabletOral5 mg
TabletOral15 mg
TabletOral20 mg
Powder, for solutionIntramuscular10 mg
KitIntramuscular
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral20 mg
Tablet, orally disintegratingOral5 mg
Prices
Unit descriptionCostUnit
Zyprexa relprevv 405 mg vial1287.9USD vial
Zyprexa relprevv 300 mg vial954.0USD vial
Zyprexa relprevv 210 mg vial667.8USD vial
ZyPREXA Zydis 30 10 mg Dispersible Tablet Box562.35USD box
ZyPREXA Zydis 30 5 mg Dispersible Tablet Box385.63USD box
Zyprexa 10 mg vial35.69USD vial
Zyprexa zydis 20 mg tablet34.87USD tablet
Zyprexa 20 mg tablet34.37USD tablet
Zyprexa zydis 15 mg tablet26.45USD tablet
Zyprexa 15 mg tablet21.14USD tablet
Symbyax 12-25 mg capsule20.62USD capsule
Symbyax 12-50 mg capsule20.62USD capsule
Zyprexa zydis 10 mg tablet18.02USD tablet
Symbyax 6-50 mg capsule14.56USD capsule
Zyprexa 10 mg tablet14.09USD tablet
Symbyax 6-25 mg capsule13.69USD capsule
Zyprexa zydis 5 mg tablet12.36USD tablet
Zyprexa 7.5 mg tablet11.23USD tablet
Symbyax 3-25 mg capsule10.01USD capsule
Zyprexa 5 mg tablet8.92USD tablet
Zyprexa Zydis 10 mg Disintegrating Tablet7.86USD tablet
Zyprexa 2.5 mg tablet7.1USD tablet
Apo-Olanzapine 15 mg Tablet6.64USD tablet
Co Olanzapine 15 mg Tablet6.64USD tablet
Novo-Olanzapine 15 mg Tablet6.64USD tablet
Pms-Olanzapine 15 mg Tablet6.64USD tablet
Apo-Olanzapine 10 mg Tablet4.43USD tablet
Co Olanzapine 10 mg Tablet4.43USD tablet
Novo-Olanzapine 10 mg Tablet4.43USD tablet
Pms-Olanzapine 10 mg Tablet4.43USD tablet
Zyprexa Zydis 5 mg Disintegrating Tablet3.93USD tablet
Co Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Novo-Olanzapine Od 10 mg Disintegrating Tablet3.54USD tablet
Pms-Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Sandoz Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Apo-Olanzapine 7.5 mg Tablet3.32USD tablet
Co Olanzapine 7.5 mg Tablet3.32USD tablet
Novo-Olanzapine 7.5 mg Tablet3.32USD tablet
Pms-Olanzapine 7.5 mg Tablet3.32USD tablet
Apo-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine 5 mg Tablet2.21USD tablet
Novo-Olanzapine 5 mg Tablet2.21USD tablet
Pms-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Novo-Olanzapine Od 5 mg Disintegrating Tablet1.77USD tablet
Pms-Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Sandoz Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Apo-Olanzapine 2.5 mg Tablet1.11USD tablet
Co Olanzapine 2.5 mg Tablet1.11USD tablet
Novo-Olanzapine 2.5 mg Tablet1.11USD tablet
Pms-Olanzapine 2.5 mg Tablet1.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2041113 No1998-07-142011-04-24Canada
CA2216372 No2007-11-202016-03-22Canada
US5229382 No1994-04-232011-04-23Us
US5945416 No1997-03-242017-03-24Us
US6169084 No1998-09-302018-09-30Us
US6251895 No1998-03-232018-03-23Us
US6960577 No1997-11-012017-11-01Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195 °CNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0942 mg/mLALOGPS
logP3.61ALOGPS
logP3.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity93.87 m3·mol-1ChemAxon
Polarizability35.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub ClassNot Available
Direct ParentBenzodiazepines
Alternative Parents
Substituents
  • Benzodiazepine
  • Thieno-para-diazepine
  • 2,3,5-trisubstituted thiophene
  • N-alkylpiperazine
  • N-methylpiperazine
  • Para-diazepine
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903 ]
  2. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, Lucignani G, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F: Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004 Sep;18(3):355-65. [PubMed:15358979 ]
  3. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ: Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005 Apr;66(4):450-4. [PubMed:15816787 ]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601 ]
  5. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, Buceta M, Cano E, Sotelo E, Brea J, Caruncho HJ, Isabel Cadavid M, Castro M, Isabel Loza M: Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology. 2006 Sep;51(4):923-32. Epub 2006 Aug 14. [PubMed:16905159 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  9. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
  4. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T: In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8. [PubMed:17092971 ]
  5. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW: The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci. 2006 Oct;24(7):2075-83. [PubMed:17067304 ]
  6. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006 Mar;163(3):529-31. [PubMed:16513877 ]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R: The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006 Jun;31(6):1310-7. [PubMed:16237394 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006 Feb 14;71(4):521-9. Epub 2005 Dec 5. [PubMed:16336943 ]
  3. Overstreet DH, Knapp DJ, Breese GR: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007 Sep;31(9):1473-81. Epub 2007 Jul 11. [PubMed:17624999 ]
  4. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19. [PubMed:16983399 ]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
  6. Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. [PubMed:16952163 ]
  7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A: The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3. [PubMed:15729086 ]
  3. Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL: Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9- diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. Epub 2005 Sep 1. [PubMed:16141369 ]
  4. Altschuler EL, Kast RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses. 2005;65(1):65-7. [PubMed:15893120 ]
  5. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  3. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  4. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.
Gene Name:
HTR5A
Uniprot ID:
P47898
Molecular Weight:
40254.69 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  3. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531 ]
33. D(2L) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
34. D(2S) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39